What are some commonly used radiopharmaceutical therapies?
Here is the table which lists some of the most common currently available radiopharmaceuticals as well as their approval status in the US.
Selected Therapeutic Radiopharmaceuticals
RADIOPHARMACEUTICAL | ISOTOPE | PRIMARY EMISSION(S) | HALF-LIFE | ROUTE OF ADMINISTRATION | INDICATION | US STATUS |
---|---|---|---|---|---|---|
Iodine-131 sodium iodide | 131 I | Beta Gamma | 8 days | Oral | Thyroid disease (thyroid cancer and hyperthyroidism) | Approved |
Yttrium-90 microspheres | 90 Y | Beta | 64 hours | Intra-arterial (hepatic artery) | Hepatocellular carcinoma Liver metastases | Approved |
Yttrium-90 ibritumomab tiuxetan | 90 Y | Beta | 64 hours | Intravenous | Non-Hodgkin lymphoma | Approved |
Radium-223 dichloride | 223 Ra | Alpha | 11.4 days | Intravenous | Bone dominant castrate-resistant prostate cancer | Approved |
Samarium-153 EDTMP | 153 Sm | Beta Gamma | 46.3 hours | Intravenous | Painful bone metastases | Approved |
Yttrium-90 or lutetium-177 somatostatin analogues (e.g., DOTATOC, DOTATATE) | 90 Y 177 Lu | Beta Beta Gamma | 64 hours 6.6 days | Intravenous | Carcinoid tumor Pancreatic neuroendocrine tumor | Investigational |
Iodine-131 MIBG | 131 I | Beta Gamma | 8 days | Intravenous | Pheochromocytoma Paraganglioma Neuroendocrine tumor | Investigational |